About Us: Leadership

Chief Executive Officer 

Brian McVeigh is the Chairman, Chief Executive Officer, and Co-Founder of Code Bio. He also serves as the Chairman of the Board of Genisphere, LLC, and is a Venture Partner with 4BIO Capital.

Brian has held leadership roles in both private and public biotechs, including a 25-year career with GlaxoSmithKline (GSK) Pharmaceuticals where he most recently served as the Vice President of Worldwide Business Development Transactions and Investment Management.

Brian holds Bachelor of Science degrees in Accounting and Finance from LaSalle University, an MBA with a Concentration in Finance from Villanova University, a Post MBA Certificate in Pharmaceutical Marketing from Saint Joseph's University, and a Certificate of Professional Development from the Wharton Business School at the University of Pennsylvania. He is a Certified Public Accountant, Certified Management Accountant, and Certified Licensing Professional.

Chief Platform Technologies Officer

Bob Getts serves as Chief Platform Technologies Officer and is a Co-Founder of Code Bio. Bob leads all of the company’s discovery, platform development and novel application activities. He also serves as a Scientific Advisor for AllerGenis LLC; as a member of the Rowan University Biomedical Engineering Industrial and Medical Advisory Board; as an Associate Clinical Preceptor of Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy; and as a graduate program advisor at Thomas Jefferson University and The University of Maryland.

​

Bob possesses more than 25 years of experience using nanotechnologies as tools to develop life science reagents, kits, and diagnostic assays. Most recently he served as the Chief Scientific Officer and acting CEO at Genisphere, LLC. where he led the development of 3DNA as a novel non-viral targeted delivery platform for the delivery of multiple types of therapeutic cargo including small drugs, siRNA, biologics, and whole genes.

​

Bob has a Ph.D. in Biochemistry from Lehigh University, has over 40 peer-review publications, abstracts, and presentations, and is listed as an inventor on more than 20 issued patents and over 35 U.S. and international patent applications.

Chief Technical Officer

Alex oversees the overall manufacturing strategy, technical development and chemistry, manufacturing, and controls (CMC) roadmap at Code Bio.

​

Alex has more than 20 years of experience in the biotech and pharmaceutical industry. Prior to Code, he served as Chief Technical Officer at BridgeBio Gene Therapy. During his time at BridgeBio, Alex developed the regulatory CMC strategy, led process and analytical development as well as external manufacturing for several clinical-stage AAV gene therapy programs. Alex also held the role of Chief Technical Officer at Istari Oncology, where he successfully negotiated Phase III comparability and control strategies with the FDA for the company’s glioblastoma monotherapy program. Dr. Tracy also served as Vice President of Pharmaceutical Development and Manufacturing at Enzyvant/Roivant Sciences, Head of Manufacturing Science & Technology at Hospira, a Pfizer Company, as well as Global Head of Manufacturing Science & Technology at Novartis Vaccines & Diagnostics.

​

Alex received a PhD in Biochemistry and Molecular Biology from University of Georgia, an M.S. in Chemistry at George Mason University, as well as a B.S. in Chemistry and English from The College of William and Mary. 

Head of Program Management and Production

Paula Carpenter serves as Code Bio’s Head of Program Management and Production. Paula's focus is on leading stage appropriate material production for preclinical activities with CMC in mind as well as providing overall program and project management for the company.  ​

​

Paula has 20+ years of experience in the biotech and pharmaceutical industry.  Prior to joining Code Bio she was responsible for developing and managing the QC analytical project plans for a BLA filing and multiple clinical programs at Spark Therapeutics, and prior to that she was responsible for the production of DNA microarrays and biochemical reagent kits at Orchid BioSciences. 

​

​Paula received an M.B.A. from Rutgers University and a B.S. in Mechanical Engineering from Lehigh University. She also has her PMP certification.

Head of Analytical Methods Development, Chemistry, Manufacturing, and Controls (CMC)

Matt Roberts is Code Bio’s Head of Analytical Methods Development, CMC. Matt’s focus is on building a state-of-the-art team responsible for developing fit-for-purpose analytical methods for characterization, in-process, stability, and Quality Control (QC) release testing of Code Bio’s innovative gene delivery technology and product pipeline.

Matt has more than 10 years of experience in the pharmaceutical industry. He started his industry career at GlaxoSmithKline as an R&D Biopharmaceutical Technical Development Program Associate (now the Future Leaders Program). Matt’s responsibilities in subsequent roles at GSK spanned analytical methods development for the assessment of biopharmaceutical and cell and gene therapies, leading teams of assay developers, and establishing analytical testing strategies for assets ranging from candidate selection to launched product. Prior to joining Code, Matt served as GSK’s Director of Cell & Gene Therapy Analytical Development, where he managed a team of US- and UK-based group leaders to develop, transfer, and validate analytical methods in support of GSK’s product pipeline.

​

Matt holds a PhD and MPhil in Molecular Biophysics and Biochemistry from Yale University and a Bachelor of Science degree in Biochemistry from the University of Delaware.